Vyome Presents on Development of Dual Action Rational Therapeutics (DARTs) to Treat Infections Caused by Antibiotic-Resistant...
December 09 2016 - 5:33AM
Business Wire
DARTs Has Potential to Develop Novel Treatments
for Gram Positive/Negative Skin Opportunist Pathogens
Vyome Biosciences, a clinical-stage specialty biopharmaceutical
company developing novel medicines for treating skin diseases
caused by resistant microbes, presented two posters at the
Re-Entering Antibacterial Discovery and Development Summit 2016 in
Boston. The first poster details how its Dual Action Rational
Therapeutics (DARTs) technology-based novel drug candidates may
have the potential to bypass and/or suppress antibiotic resistance
for severe antibiotic-resistant infections caused by orthopedic
implants caused by S. epidermidis, a skin opportunist pathogen. The
second poster details the potential of Vyome’s library of novel
antibiotics currently in development for skin opportunist
pathogens, and their low propensity to develop antibiotic
resistance.
Vyome’s patented DARTs technology has the potential to improve
treatment of antibiotic-resistant infections from skin opportunist
pathogens that occur during orthopedic surgeries. Systemic
antibiotics may be ineffective in treating implant-related bone
infections from opportunistic pathogens during accident-associated
or elective orthopedic surgeries. Local antibiotic therapies, which
are loaded into bone cements, are also limited in efficacy due to
poor drug penetration through the bone, emergence of multi-drug
resistant pathogens and formation of bacterial biofilms. The
company presented, “Development of a New Generation Antibiotic for
the Treatment of Orthopedic Implant-Associated Infections Caused by
Skin Opportunist Pathogens” during a poster session this week.
“The rapid appearance and growth of resistant bacterial strains
has far reaching implications on public health around the world,
and there is an immediate need for additional, more effective
treatment options for infections caused by skin opportunist
pathogens,” said Venkateswarlu Nelabhotla (N. Venkat), Co-Founder
and Chief Executive Officer of Vyome Biosciences. “Where currently
available systemic and locally administered antibiotics fail, our
multi-action DARTs platform has the potential to achieve a high
level of efficacy while minimizing the risk of emerging
resistance,” remarked Dr. Shiladitya Sengupta, Co-Founder &
Board Member, Vyome Biosciences.
As antibiotic resistant strains of both Gram-positive and
Gram-negative bacteria become more prevalent across many areas of
care, Vyome aims to address this large unmet need by developing a
library of Dual Action Rational Therapeutics technology platform
based novel compounds by utilizing a rational structure-based drug
design to generate new antibiotics which have multi-mode action to
bypass and/or suppress antibiotic resistance. Vyome aims to develop
and leverage only molecules with potent bactericidal activity
against resistant strains, low propensity in emergence of
resistance, a demonstrable ability to disrupt biofilms, and the
exhibition of anti-inflammatory properties as the path forward in
treating local/topical infections caused by antibiotic resistant
skin opportunist pathogens. The company presented a study,
“Development of a Library of Novel Antibiotics with Low Propensity
to Develop Resistance” at the summit this week.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage
specialty bio-pharmaceutical company, which has novel platform
technologies and a deep pipeline that addresses drug-resistant skin
opportunistic pathogens such as antibiotic resistant acne. Vyome’s
lead program VB 1953, which targets the unmet need of antibiotic
resistant acne, is currently under evaluation in U.S. FDA Phase 1
clinical studies. Vyome also has a deep pipeline of preclinical new
chemical entities, unique in their ability to overcome the
development of resistance based on patented Dual Action Rational
Therapeutics (DARTs) technology. In addition, Vyome has developed
clinically proven antifungal products based on an innovative
technology platform, Molecular Replacement Therapy (MRT™). Vyome
has assembled a world-class team of scientific experts from India
and the United States who have a track record of conducting
scientific research, developing breakthrough products and building
sustainable businesses. More information is available at
http://www.vyome.in
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161208005837/en/
For Vyome BiosciencesNic DiBella,
+1-617-945-5183nic@jpa.com